Product pipeline

Menarini Stemline^® product pipeline

Menarini Stemline^® invests in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients with cancer.

Our pipeline refers to drugs in development, including those in preclinical testing, clinical development, regulatory approval and lifecycle management.

The information in the table reflects the Menarini Stemline^® development pipeline and is not intended for promotional or marketing purposes. The safety and efficacy of the investigational compounds, or investigational uses of marketed products, have not been established and marketing approval has yet to be granted by regulatory authorities.

Mechanism of action: Targeted biologic (CD123)

Indication: Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Stage: Approved (EU)
Additional details: Tagraxofusp was approved by the EMA in 2021 as monotherapy for the first-line treatment of adult patients with BPDCN
External links^*: EMA SmPC

Indication: Acute myeloid leukaemia (AML)
Stage: Phase 2
External links^*: Tagraxofusp to eradicate measurable residual disease in patients with acute myeloid leukemia

Indication: Chronic myelomonocytic leukaemia (CMML)
Stage: Phase 2
External links^*: Tagraxofusp (SL-401) in patients with CMML or MF

Indication: Myelofibrosis (MF)
Stage: Phase 2
External links^*: Tagraxofusp (SL-401) in patients with CMML or MF

*Please note: Menarini Stemline^® UK accepts no liability for external links.

Mechanism of action: Selective oestrogen receptor degrader (SERD)

Indication: Breast cancer
Stage: Phase 2 – combination
Additional details: ELECTRA is a Phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from ER+/HER2-  breast cancer
External links^*: Study of abemaciclib and elacestrant in patients with brain metastasis due to HR+/HER2- breast cancer (ELECTRA)
Indication: Breast cancer
Stage: Phase 2 – combination
Additional details: ELEVATE is a Phase 1b/2 umbrella study of elacestrant in various combinations in patients with ER+/HER2- metastatic breast cancer
External links^*: Open-label umbrella study to evaluate safety and efficacy of elacestrant in various combination in patients with metastatic breast cancer (ELEVATE)
Indication: Breast cancer
Stage: Phase 2 – monotherapy
Additional details: ELCIN is a Phase 2 study of elacestrant in patients with CDK4/6i naïve ER+/HER2- metastatic breast cancer
External links^*: ELACESTRANT in women and men with CDK4/6 inhibitor-naive estrogen receptor positive, HER-2 negative metastatic breast cancer study (ELCIN)

*Please note: Menarini Stemline^® UK accepts no liability for external links.

Mechanism of action: SME (PIM/FLT3i)

Indication: Acute myeloid leukaemia (AML)
Stage: Phase 2
Additional details: MEN1703 is being investigated for the treatment of adult patients with relapsed/refractory AML
External links^*: SEL24/MEN1703 in patients with acute myeloid leukemia